Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today
TAIPEI and SAN DIEGO, June 25, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr. Benny T. Hu. The company delivered...
Per Franzén appointed new CEO of EQT AB as of May 2025
The Board of Directors of EQT AB ("EQT") has appointed Per Franzen as new CEO and Managing Partner, effective as of the Annual Shareholders' Meeting on 27 May 2025. During this transition period, Christian Sinding will remain as CEO. Per Franzen has...